On August 10, 2026, the UK became the first country in Europe to approve Eli Lilly's oral GLP-1 receptor agonist, orforglipron, marketed as Foundayo. This medication is significant for both weight management and the treatment of type 2 diabetes. The approval was granted by the Medicines and Healthcare products Regulatory Agency (MHRA), positioning it alongside Novo Nordisk's recently approved sterile injectable semaglutide (Wegovy) and introducing a new oral alternative to existing medications.

Overview of GLP-1 Receptor Agonists

GLP-1, or glucagon-like peptide-1, is a hormone that mimics the body's natural response to food intake, promoting satiety and reducing appetite. This class of medications has become popular due to their efficacy in weight loss and glycemic control in patients with type 2 diabetes. Orforglipron represents a non-peptide oral solution, enhancing patient adherence by avoiding the need for injections.

Approval Details

Foundayo has been approved for use in adults with a body mass index (BMI) of 30 or higher, or a BMI between 27 and 30 with related comorbidities. Additionally, this medication aims to improve glycemic control in patients who have not adequately responded to existing treatment options.

Clinical Findings

Clinical trials, such as the ATTAIN-MAINTAIN study, have shown that orforglipron is effective in maintaining weight loss achieved through other GLP-1 medications. Patients demonstrated improved cardiometabolic outcomes, aligning with the efficacy of injectable alternatives.

Methodology

  • Study Type: Randomized clinical trials
  • Dosage: Treatment begins at 0.8 mg daily, increasing according to patient tolerance.
  • Duration: 1 month at each incremental dose until a maximum of 17.2 mg is reached.

Market Context

Since its approval in the U.S. earlier in 2026, sales potential for Foundayo is noteworthy, with the UK expected to be one of the top markets. It has already generated $98 million in preliminary sales, yet remains unavailable through the National Health Service (NHS) pending evaluation by the National Institute for Health and Care Excellence (NICE).

Future Implications

According to Julian Beach, MHRA's executive director, the authorization of orforglipron is a critical step in expanding treatment options for individuals reluctant to opt for injections. As noted by Naveed Sattar, a professor of cardiometabolic medicine, having a convenient oral option is advantageous for patient adherence, although other medications such as semaglutide may provide more substantial weight loss benefits.

Side Effects

  • Nausea
  • Constipation
  • Diarrhoea
  • Vomiting
  • Dyspepsia
  • Abdominal pain

Limitations of the Study

While the oral formulation offers convenience, concerns remain regarding the comparative effectiveness and safety profiles of oral versus injectable GLP-1 medications, particularly in long-term usage and severe adverse events.

Conclusion

The introduction of Foundayo is a significant advancement in diabetes and obesity management, potentially shifting patient treatment paradigms depending on the outcomes of further NICE evaluations and its market availability through national healthcare systems.

References